- Research article
- Open Access
Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes
Molecular Medicine volume 28, Article number: 55 (2022)
The aim of this study was to draw a comprehensive mutational landscape of nasopharyngeal carcinoma (NPC) tumors and identify the prognostic factors for distant metastasis-free survival (DMFS).
A total of forty primary nonkeratinizing NPC patients underwent targeted next-generation sequencing of 450 cancer-relevant genes. Analysis of these sequencing and clinical data was performed comprehensively. Univariate Cox regression analysis and multivariate Lasso-Cox regression analyses were performed to identify factors that predict distant metastasis and construct a risk score model, and seventy percent of patients were randomly selected from among the samples as a validation cohort. A receiver operating characteristic (ROC) curve and Harrell’s concordance index (C-index) were used to investigate whether the risk score was superior to the TNM stage in predicting the survival of patients. The survival of patients was determined by Kaplan–Meier curves and log-rank tests.
The twenty most frequently mutated genes were identified, such as KMT2D, CYLD, and TP53 et al. Their mutation frequencies of them were compared with those of the COSMIC database and cBioPortal database. N stage, tumor mutational burden (TMB), PIK3CA, and SF3B1 were identified as predictors to build the risk score model. The risk score model showed a higher AUC and C-index than the TNM stage model, regardless of the training cohort or validation cohort. Moreover, this study found that patients with tumors harboring PI3K/AKT or RAS pathway mutations have worse DMFS than their wild-type counterparts.
In this study, we drew a mutational landscape of NPC tumors and established a novel four predictor-based prognostic model, which had much better predictive capacity than TNM stage.
Nasopharyngeal carcinoma (NPC) is relatively uncommon. There were approximately 129,000 new patients worldwide in 2018, accounting for only 0.7% of all cancers diagnosed. The geographical global distribution of NPC is extremely unbalanced; > 70% of new cases are in eastern and southeastern Asia (Chen et al. 2019). Even though local and regional controls have been substantially improved in NPC with extensive use of combined chemotherapy in the contemporary era of intensity-modulated radiotherapy, distant metastasis has become the major cause of treatment failure and cancer-related death (Pan et al. 2016).
Currently, the tumor‐lymph node‐metastasis (TNM) staging system is the key clinical tool for prognostication, risk stratification, and making treatment decisions. However, the TNM stage is unable to accurately predict whether patients will have distant metastasis. Over the past decades, with the continuous development of sequencing technology, great efforts have been made to search for molecular biomarkers associated with distant metastasis, such as long noncoding RNA, EBV DNA, microRNA and gene expression (Chen et al. 2019; Liu et al. 2012; Tang et al. 2018; Wen et al. 2018). Efforts to promote molecular classifications are more comprehensive and becoming more prevalent in clinical cancer management (Lim and Ma 2019).
Next-generation sequencing (NGS), also called massive parallel sequencing, was developed in the last decade. It can be used not only in research settings but also in clinical practice; however, whole exome sequencing (WES) or whole genome sequencing (WGS) provide more information than what can be practically used (Xuan et al. 2013). It is difficult to process this amount of data at a level required for clinical applications, and it is too costly for individual patient diagnosis. Based on this, targeted next-generation sequencing has been developed to obtain genomic data in a timely and cost-effective way by testing clinically important genes (Nagahashi et al. 2019). In recent years, targeted next-generation sequencing has been adopted in many cancers, such as lung cancer, gastric cancer and brain tumors (Cai et al. 2019; Kneuertz et al. 2020; Sahm et al. 2016). The application of targeted next-generation sequencing to replace WGS and WES technology for genetic testing in clinical practice has become a recent trend.
The aim of this study was to draw a comprehensive mutational landscape of 40 NPC tumors and identify the prognostic factors for metastasis-free survival. Moreover, the study found combined tumor mutational burden (TMB), genomic and N stage to generate a model with more accurate prediction than TNM stage for distant metastasis-free survival (DMFS).
Patients and samples
Between March 2014 and August 2018, a total of 40 patients diagnosed at Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences were enrolled. All of the patients were Asians and had long-term residence in Shandong Province, China. A flow chart for study design was included in Additional file 2: Fig. S1. The inclusion criteria were age over 18 years, and pathologically confirmed primary nonkeratinizing NPC. The exclusion criteria were as follows: incomplete clinical follow-up data, presence of other malignant tumors and refusal to consent to study participation. The patients were strictly followed-up and reviewed regularly until March 14, 2021. Distant metastases were defined as clinical evidence of distant disease based on clinical and radiographic findings. The clinicopathological characteristics of these patients were obtained from the electronic records of the patients. This study complied with the principles set forth in the Declaration of Helsinki. It was approved by the Institutional Review Board of Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences. Written informed consent was obtained from each patient.
DNA extraction and library preparation
DNA from formalin-fixed, paraffin-embedded (FFPE) tumor samples was extracted by a DNA Extraction Kit (QIAamp DNA FFPE Tissue Kit) according to the manufacturer's protocols. A minimum concentration of 50 ng was used for each 40 mm FFPE tumor sample. All tumor samples were sent to the laboratory (Shanghai OrigiMed Co., Ltd.) for genomic DNA extraction and hybridization capture. All coding exons of 450 genes and introns of 39 genes were incorporated into the custom hybridization capture panel. The 450 genes were considered tumor-associated genes or the upstream and downstream parts of the tumor-related pathway, and the 39 genes were frequently identified in gene rearrangements. To ensure high efficiency of capture in the low-read depth region, the probe density was increased. Libraries were each diluted to 1.05 nmol/L and then sequenced with a mean coverage of 1101 × for FFPE samples on an Illumina NovaSeq Platform (Illumina Incorporated)(Cao et al. 2019).
Reads were aligned to the human genome reference sequence (hg19) by Burrows–Wheeler Aligner, and PCR duplicates were removed using Picard. After quality recalibration and realignment using GATK, single-nucleotide variants (SNVs) and short indels were identified by MUTECT. Next, short indels were calibrated by the Pindel results. To normalize the read depths within the target regions, EXCATOR was used(Tong et al. 2021). We calculated the log-ratio per region of each gene and detected copy number variants (CNVs) by customized algorithms. Germline variants were identified by HaplotypeCaller from the Genome Analysis Toolkit (GATK v.3/3) in gvcf mode with default settings, and only those present in both normal and tumor samples were retained. Tumor cellularity was estimated by allele frequencies of sequenced SNPs. Notably, a customized algorithm can be used to detect gene rearrangements, fusions, and long indels. This panel has been stringently validated and is reliable for use in the clinic. Thirty-three cell lines and 208 clinical FFPE samples used performed to assess the concordant results between NGS and Sanger sequencing, IHC, FISH, and PCR(Cao et al. 2019).Tumor mutation burden was defined as the number of all somatic base substitutions and indels per mega base excluding synonymous mutations(Cao et al. 2019). At a minimum, five reads were required to support alternative calling.
The statistical analysis and the graph were performed with R software (version 4.0.3), SPSS 23.0 (IBM SPSS Statistics) and GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA). Venn diagrams (http://bioinformatics.psb.ugent.be/webtools/Venn/) of the high frequency mutations genes were drawn for the different databases. X-title plots were used to generate an optimal cutoff value of TMB. To identify metastasis-related factors, univariate Cox regression analysis was performed. The criterion of P < 0.02 was selected as the filtering threshold. Next, Lasso-Cox regression analysis was used to filter the prognostic genes and construct a risk score model. Seventy percent of patients were randomly selected from the samples as a validation cohort using the R package “caret”. ROC curves and Harrell’s concordance index (C-index) were used to investigate whether the risk score was superior to the TNM stage in predicting the survival of patients. The survival of patients was determined by Kaplan–Meier curves and log-rank tests. P-value of less than 0.05 were considered significant.
The clinicopathological characteristics of the patients
In total, forty patients were enrolled in this study, including 5 cases in stage I-II (stage I, n = 3; stage II, n = 2) and 35 cases in stage III–IV (stage III, n = 18; stage IV, n = 17).The median age was 47 years old at diagnosis (range from 18 to 71 years). With a median follow-up of 2.79 years (range 2.55–7.04 years), 10 patients developed distant metastases, 1 experienced local recurrence, and 1 was died. The clinicopathological characteristics of the patients are presented in Table 1.
Landscape of mutations
A total of 171 somatic mutations were detected in 123 genes, including 112 missense_mutations, 20 nonsense_mutations, 15 frame_shift_deletions, 14 splice_regions, 6 frame_shift_insertions, 3 splice_sites and 1 in_frame_ins. The median number of mutations per patient was 3 (range 0–24). Thisreveals a relatively low mutational rate and wide mutational diversity (Additional file 2: Fig. S2a, b). Missense mutations were the major mutation types and C > T transitions were the dominant aberrations, accounting for 64.29% and 71.34% of the total somatic SNVs, respectively. In addition, we noticed that the transition/transversion (Ti/Tv) ratio was 1.8 (Additional file 2: Fig. S2c-e). The top 30 genes with the most frequent mutations were found in 32 patients. Among these, the 5 most frequently mutated genes were CYLD (12.50%), KMT2D (12.50%), TP53 (10.00%), BAP1 (10.00%) and EP300 (10.00%) (Fig. 1a).
The twenty most frequently mutated genes were compared to the COSMIC database (https://cancer.sanger.ac.uk/cosmic) and cBioPortal database (http://cbioportal.org). As expected, KMT2D and TP53 had a high frequency of mutations in the 3 datasets. Mutations in other frequently mutated genes in our study, including SPEN, NOTCH1, CYLD, PIK3CA, and EP300 were covered by the COSMIC database. In addition, the BAP1 mutation frequency was high in this study and in the cBioPortal database but not high enough in the COSMIC database.
Notably, this study identified a number of significant correlations including patterns of co-occurrence or mutuality between different mutant genes especially one mutually co-occurring pair (BAP1 and DOT1L) (corrected P < 0.05, Additional file 2: Fig. S2f-g).
Copy number variation detection and rearrangement
The frequency of copy number variation per gene is shown in Fig. 2a. Deletions were found in 3 genes (NKX2-1, CDKN2B, CDKN2A), while amplifications were detected in the other 24 genes. Among them, the deletion of CDKN2A and deletion of CDKN2B were found in the same patient, who developed bilateral pulmonic metastases. The eight CNV genes according to frequency included B2M (25.00%), CCND1 (12.50%), FGF3 (12.50%), FGF19 (10.00%), FGF4 (10.00%), TNFAIP3 (7.50%), and PRDM1 (7.50%).
In addition to SNV and CNV, four patients were profiled for fusion/rearrangement of 8 genes, of which 5 genes were fusion transcripts. The study identified CD58-WEE2 in Patient 2, who developed multiple bone metastases. CDKN2A-STON2 was identified in Patient 4, who developed multiple bone metastases, and liver metastases. All of the fusion and arrangement information is presented in Fig. 2b.
Enrichment of mutated genes by GO and KEGG analysis
GO and KEGG pathway analyses for all mutated genes were performed. The top 30 most significantly enriched GO and KEGG terms according to gene count and P value are presented in Fig. 3a, b, respectively. Regarding the biological process of GO, the genes were significantly enriched in ‘peptidyl-tyrosine phosphorylation’. Concerning the cellular component of GO, the genes were specifically focused on ‘glutamatergic synapses’. In addition, the genes were primarily assembled in ‘protein tyrosine kinase activity’ based on the molecular function of GO (Fig. 3a).
Many KEGG pathways were significantly enriched, such as the PI3K-Akt signaling pathway, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cellular senescence, EGFR tyrosine kinase inhibitor resistance, and other well-known pathways. Among these, the PI3K-Akt signaling pathway was the most significantly enriched pathway, which involved in 27 genes. Next, the analysis focused on high-frequency mutations that caused amino acid changes. We found that patients with PI3K/AKT pathway or RAS pathway mutations had worse DMFS than their wild-type counterparts (P = 0.016, P = 0.006, respectively; (Fig. 4a, b)). We also the MAPK signaling pathway and Rap1 signaling pathway, they were not statistically significant (Fig. 4c, d).
Risk score and prognostic analyses
A flowchart of the analysis workflow is illustrated in Fig. 5a. Univariate Cox regression analysis identified 9 metastasis-related factors, including sex, TMB, vafmean, T stage, N stage, TNM stage, ATM, PIK3CA, SF3B1, and TP53, as potential prognostic indicators of DMFS. After primary filtering, a Lasso-Cox regression analysis was performed to further narrow down the screening results and identified TMB, N stage, PIK3CA and SF3B1 as predictors for model construction (Fig. 5b, c). Risk scores for the four-predictor-based model were calculated by the ‘survival’ package. Using ROC analysis, the risk score output a higher AUC value (AUC = 0.929) than current TNM stage (AUC = 0.697; Fig. 5d). The risk score (C-index = 0.87) also showed a higher C-index than the current TNM stage (C-index = 0.70). Finally, Kaplan–Meier survival analysis showed clearly separated curves, and the DMFS of patients whose risk score was no greater than 0.7 was longer than that of patients with a risk score greater than 0.7 (P = 0.001; Fig. 5e).
For validation of the model, the same calculation was performed using data from our validation cohort. In the validation cohort, the risk score also displayed significantly higher AUC and C-index values than those of the TNM stage (0.865 versus 0.740, 0.833 versus 0.738; Fig. 5f). Similarly, the risk score is capable of separating the patients clearly in the validation cohort (P = 0.005; Fig. 5g).
The genes related to distant metastasis in NPC
This study found that PIK3CA and SF3B1 mutations were associated with NPC distant metastasis. Patients with PIK3CA and SF3B1 mutations had shorter DMFS than patients with no-mutations (P < 0.001; Fig. 6a). Focusing on PIK3CA, one missense mutation site was located in PI3Kc_IA_alpha functional region, and glutamine was mutated to histidine here. Besides, In addition, methionine was mutated to isoleucine in the PI3Ka_I functional region (Fig. 6b). For SF3B1, two missense mutation sites were located in the HSH155 functional region with a dense distribution, and the amino acid variations were shown to be p.V576 M (mutation of valine to methionine) and p.S637Y(mutation of serine to tyrosine), respectively (Fig. 6c).
With NGS technology, the genomic landscapes of NPC have been comprehensively elucidated at the whole-exome or whole-genome levels (Tsang et al. 2020). Considering both the cost and detection rate, large targeted next-generation sequencing can be a comparable alternative to WES or WGS in most clinical cases. We found no significant differences in high-frequency mutations between our study and others. For example, the findings revealed that missense mutations, SNPs, and C > T mutations were the common mutation forms, and similar percentages were found in the COSMIC database. Unsurprisingly, KMT2D and TP53 were the most frequently mutated genes in the 3 datasets. However, high-frequency mutated genes in this study and COSMIC datasets, including SPEN, NOTCH1, CYLD and EP300 had no mutation frequencies in the cBioPortal database. This might be because the data in cBioPortal were relatively limited, with a sample of only 56 patients, all from the same hospital. Our analyses of CNV found that FGF19, FGF4, FGF3 and CCND1 gene amplification occurred in the same 4 patients. With this, we can speculate about correlations among these four genes.
To better understand the functions of these mutated genes, we conducted KEGG and GO distribution analysis. Previous studies revealed that the PI3K/AKT and MAPK signaling pathway are implicated in several biological processes, such as cellular proliferation and metastasis (Ersahin et al. 2015; Tomić et al. 2017). Our results showed that the PI3K-Akt and MAPK signaling pathways were enriched for multiple genes, and may play critical roles. Similar to findings in other studies, patients harboring at least one of the PI3K-Akt signaling pathway mutations, including PIK3CA, RAC1, and TP53, had worse DMFS than their wild-type counterparts (Zhang et al. 2017; Lin et al. 2014; Zheng et al. 2016). For MAPK signaling pathway mutations, the survival curves demonstrated a decreasing trend toward decreased, but the changes were modest and not statistically significant (P = 0.452). Moreover, we found that tumors with Ras signaling pathway mutations had worse DMFS than their wild-type. Therefore, our findings agree with Tsang et al., who that small molecule RAS inhibitors can be tried in patients with NPC (Tsang et al. 2020; O'Bryan 2019).
With recent advances in molecular biology and genome sequencing, many scholars have put immense effort into identifying molecular biomarkers to improve prognostication accuracy, such as EBV DNA, microRNA, and mRNA (Tang et al. 2018; Liu et al. 2014). Concurrently, they found that a molecular signature integrated with clinical indicators can often improve upon the prognostic capability. Molecular-based prediction models were previously constructed based on microRNA or mRNA expression, but their clinical practicability is not sufficient(Tang et al. 2018). We hoped that, with targeted NGS, we can construct a risk score model of NPC that is easier to incorporateinto clinical practice. The risk score was established based on two genes (PIK3CA and SF3B1), TMB, and N stage to identify high-risk prognostic individuals with a worse DMFS. Obviously, the risk score model had better value for predicting metastasis than does the TNM stage.
Remarkably, we found that PIK3CA and SF3B1 mutations were independent prognostic factors. K-M analyses showed that patients with PIK3CA or SF3B1 mutations had a better prognosis in terms of DMFS. As a master regulator of cancer, the importance of the PI3K pathway is self-evident (Yang et al. 2019). PIK3CA, which is a key gene in multiple solid tumors, including NPC, is known to activate the PI3K pathway (Madsen et al. 2018; Mjos et al. 2017). After the first PI3K inhibitor (alpelisib) was approved by the FDA to treat breast cancer patients with PIK3CA-mutations, people expected precision-based PI3K inhibitors to would be beneficial to PIK3CA-mutated NPC patients in the future (Tsang et al. 2020; Zhang et al. 2020). PIK3CA, as an independent predictor, was not surprising. Interestingly, we are the first group to identify SF3B1 as a potential novel biomarker for predicting DMFS in NPC. Mutations in SF3B1 have been identified at a relatively high frequency in some tumors, such as hematologic malignancies, uveal melanoma (UM), and breast cancers (BC) (Ellis et al. 2012; Banerji et al. 2012; Cazzola et al. 2013). The majority of studies reported that SF3B1 mutations conferred a favorable prognosis; however, SF3B1-mutant UM was reported to be prone to metastasis (Yavuzyigitoglu et al. 2016). Moreover, SF3B1 mutation can dysregulate the NF-κB pathway in CLL (Wang et al. 2016), which was persistently activated by somatic gene alterations or viral oncoproteins that have been shown to play a crucial role in NPC tumorigenesis (Tsang et al. 2020; Zeligs et al. 2016). Further insights regarding the functional role of SF3B1 in NPC might offer fundamental evidence for DMFS prediction of NPC in the future.
The major limitation of the present study is the small sample size and the absence of a validation cohort. To reduce the sample error, we used univariate Cox regression analysis and multivariate Lasso-Cox analysis. In the future, the sample size will be enlarged and the follow-up duration will be extended to confirm the results of this study.
In this study, we drew a mutational landscape of NPC tumors and established a novel four predictor-based prognostic model, including N stage, TMB, PIK3CA and SF3B1. The model had much better predictive capacity than TNM stage.
Distant metastasis-free survival
Receiver operating characteristic
Whole exome sequencing
Whole genome sequencing
Tumor mutational burden
Copy number variants
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405–9.
Cai H, Jing C, Chang X, Ding D, Han T, Yang J, et al. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. J Transl Med. 2019;17(1):189.
Cao J, Chen L, Li H, Chen H, Yao J, Mu S, et al. An accurate and comprehensive clinical sequencing assay for cancer targeted and immunotherapies. Oncologist. 2019;24(12):e1294–302.
Cazzola M, Rossi M, Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013;121(2):260–9.
Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (london, England). 2019;394(10192):64–80.
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353–60.
Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 2015;11(7):1946–54.
Kneuertz PJ, Carbone DP, D’Souza DM, Shilo K, Abdel-Rasoul M, Zhao W, et al. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma. Lung Cancer (amsterdam, Netherlands). 2020;143:60–6.
Lim Z-F, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134.
Lin D-C, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46(8):866–71.
Liu N, Chen N-Y, Cui R-X, Li W-F, Li Y, Wei R-R, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633–41.
Liu N, Cui R-X, Sun Y, Guo R, Mao Y-P, Tang L-L, et al. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer. 2014;134(6):1359–68.
Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. 2018;24(10):856–70.
Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, et al. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Sci Rep. 2017;7(1):10240.
Nagahashi M, Shimada Y, Ichikawa H, Kameyama H, Takabe K, Okuda S, et al. Next generation sequencing-based gene panel tests for the management of solid tumors. Cancer Sci. 2019;110:1.
O’Bryan JP. Pharmacological targeting of RAS: Recent success with direct inhibitors. Pharmacol Res. 2019;139:503–11.
Pan JJ, Ng WT, Zong JF, Lee SWM, Choi HCW, Chan LLK, et al. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(21):3307–15.
Sahm F, Schrimpf D, Jones DTW, Meyer J, Kratz A, Reuss D, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131(6):903–10.
Tang X-R, Li Y-Q, Liang S-B, Jiang W, Liu F, Ge W-X, et al. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382–93.
Tomić TT, Olausson J, Wilzén A, Sabel M, Truvé K, Sjögren H, et al. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. PLoS ONE. 2017;12(4): e0175638.
Tong Z, Wang L, Shi W, Zeng Y, Zhang H, Liu L, et al. Clonal evolution dynamics in primary and metastatic lesions of pancreatic neuroendocrine neoplasms. Front Med (lausanne). 2021;8: 620988.
Tsang CM, Lui VWY, Bruce JP, Pugh TJ, Lo KW. Translational genomics of nasopharyngeal cancer. Semin Cancer Biol. 2020;61:8.
Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, et al. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell. 2016;30(5):750–63.
Wen X, Liu X, Mao Y-P, Yang X-J, Wang Y-Q, Zhang P-P, et al. Long non-coding RNA DANCR stabilizes HIF-1α and promotes metastasis by interacting with NF90/NF45 complex in nasopharyngeal carcinoma. Theranostics. 2018;8(20):5676–89.
Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett. 2013;340(2):284–95.
Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26.
Yavuzyigitoglu S, Koopmans AE, Verdijk RM, Vaarwater J, Eussen B, van Bodegom A, et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123(5):1118–28.
Zeligs KP, Neuman MK, Annunziata CM. Molecular pathways: the balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-κB Signaling for Cancer Treatment. Clin Cancer Res. 2016;22(17):4302–8.
Zhang L, MacIsaac KD, Zhou T, Huang P-Y, Xin C, Dobson JR, et al. Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes. Mol Cancer Res. 2017;15(12):1722–32.
Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. Chem Sci. 2020;11(23):5855–65.
Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci USA. 2016;113(40):11283–8.
We thank the COSMIC database and cBioPortal database providing the data.
This work was funded by the National Key Research and Development Program of China (No. 2018YFE0114100), Shandong Natural Science Foundation (ZR2021LSW002).
Ethics approval and consent to participate
The study complied with the principles set forth in the Declaration of Helsinki. It was approved by the Institutional Review Board of Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences. Written informed consent was obtained from each patient.
Consent for publication
Acknowledgements Informed consent was obtained from all patients for being included in the study.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
: Fig. S1. Flow chart for study design.
: Fig. S2. Mutational Landscape of NPC. (a-e) Mutational patterns and proportion of genetic alterations in nasopharyngeal carcinoma. (f) Statistically significant mutual exclusivity or co-occurrences among the identified genes using pairwise Fisher’s exact test. (g) Oncostrip plot showing the detailed co-occurrences of BAP1 and DOT1 L in NPC.
About this article
Cite this article
Zhou, Z., Li, P., Zhang, X. et al. Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes. Mol Med 28, 55 (2022). https://doi.org/10.1186/s10020-022-00479-4
- Tumor mutational burden
- Risk score
- Nasopharyngeal carcinoma
- Distant metastasis-free survival
- Target next-generation sequencing